BUSINESS UPDATE 2008
Preparing for EU launch of ChondroCelect In February 2008, TiGenix announced the publication of the positive results of the multi-centre, prospective, randomized, controlled clinical study confirming the structural superiority of ChondroCelect treatment compared with the current standard, microfracture treatment, over 12 months in the American Journal of Sports Medicine (AJSM), one of the highest ranked peer-reviewed journals for orthopedics and sports medicine. In this article1 it was concluded that ‘the superior structural outcome may result in long-term clinical benefit’, and that ‘long-term follow up is needed to confirm these findings’.
The conclusions of the AJSM article were confirmed by the longitudinal statistical analysis of the three-year data of trial, demonstrating clinical superiority of ChondroCelect treatment over microfracture at 36 months. These important new results were presented at the October 31st meeting of the International Cartilage Repair Society (ICRS) in Miami, Florida, US.
